EQL Pharma AB

EQL

SE0005497732

Drug Retailers

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
43.3 ^SEK	+0.70%		+1.41%	+29.64%

Apr. 22	EQL Pharma AB Announces Mellozzan Launched in Germany and Austria	CI
Feb. 13	EQL Pharma AB Provides Sales Guidance for the Year 2023/24	CI

EQL Pharma AB In-Licenses Seven Products for Denmark

March 15, 2021 at 10:10 am EDT

EQL Pharma AB (publ) has purchased seven (7) licenses, of which five (5) are exclusive, for products on the Danish market. The licenses already have marketing authorizations in Denmark.

Latest news about EQL Pharma AB

EQL Pharma AB Announces Mellozzan Launched in Germany and Austria	Apr. 22	CI
EQL Pharma AB Provides Sales Guidance for the Year 2023/24	Feb. 13	CI
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 17	CI
EQL Pharma Plans 2024 Launch of Melatonin Product in Germany, Austria After Marketing Approvals	23-10-06	MT
EQL Pharma AB Announces its Mellozzan Gains Marketing Approval by Health Authorities in Germany and Austria	23-10-06	CI
EQL Pharma AB Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-16	CI
Sweden’s EQL Pharma Launches ADHD Medicine in Denmark, Norway	23-08-15	MT
EQL Pharma AB Launches in Denmark and Norway by License Partner Medice Arzneimittel Pütter Gmbh & Co. Kg	23-08-15	CI
Fårö Capital Offloads 1 Million EQL Pharma Shares to Institutional Buyers	23-06-14	MT
EQL Pharma Out-Licenses Methenamine Hippurate to Dr. Pfleger Arzneimittel for the German Market	23-05-31	CI
EQL Pharma Enters into a Strategic Licensing Agreement with Adalvo for Mellozzan Outside of Europe	23-05-24	CI
EQL Pharma Licenses UTI Prevention Drug to French Women's Health Company	23-05-22	MT
EQL Pharma Out-Licenses Methenamine Hippurate to Laboratoires Majorelle for the French Market	23-05-22	CI
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer	23-05-17	MT
EQL Pharma AB cancelled the acquisition of all the remaining stake in Sensidose AB.	23-05-16	CI
EQL Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-11	CI
Sweden's EQL Pharma Signs License Agreement for Melatonin Product in Turkey, Kazakhstan	23-04-28	MT
EQL Pharma AB Signs License Agreement with A Pharmaceutical Company in Turkiye for Mellozzan	23-04-28	CI
Sweden’s EQL Pharma Increases Bid for Sensidose	23-04-24	MT
EQL Pharma Launches SEK91 Million Takeover Bid for Sensidose	23-04-20	MT
EQL Pharma AB made an offer to acquire all the remaining stake in to acquire Sensidose AB for SEK 91.7 million.	23-04-19	CI
EQL Pharma Recruits Carl Lindgren as Chief Business Development Officer	23-03-13	CI
EQL Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14	CI
EQL Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-11	CI

EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.

Sector

Drug Retailers

Calendar

2024-05-13 - Q4 2024 Earnings Release

More about the company

Sector Other Drug Retailers

	1st Jan change	Capi.
EQL PHARMA AB	+29.64%	115M
JD HEALTH INTERNATIONAL INC.	-31.97%	10.1B
YIFENG PHARMACY CHAIN CO., LTD.	+8.14%	6.12B
MATSUKIYOCOCOKARA & CO.	-11.41%	5.97B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-30.42%	5.65B
NAHDI MEDICAL COMPANY	-0.88%	4.71B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+52.19%	4.26B
CLICKS GROUP LIMITED	-12.31%	3.58B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-14.86%	3.26B
WELCIA HOLDINGS CO., LTD.	-6.93%	3.07B

Other Drug Retailers

EQL Pharma AB

Equities

EQL

SE0005497732

Drug Retailers

EQL Pharma AB In-Licenses Seven Products for Denmark

Latest news about EQL Pharma AB

Chart EQL Pharma AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Drug Retailers